New patent for Vanda Pharms drug HETLIOZ

Annual Drug Patent Expirations for HETLIOZ

Hetlioz is a drug marketed by Vanda Pharms Inc and is included in two NDAs. It is available from one supplier. There are thirty patents protecting this drug and two Paragraph IV challenges.

Drug patent litigation for HETLIOZ.

This drug has one hundred and eigthy-seven patent family members in twenty-four countries.

The generic ingredient in HETLIOZ is tasimelteon. One supplier is listed for this compound. Additional details are available on the tasimelteon profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com